HSP90AA1 and cancer: In addition, the Hsp70 suppressing pan-CDK inhibitor AT7519 can be beneficial in combination with Hsp90 inhibitors that upregulate Hsp70 expression in cancers (usually upregulated by inhibitors targeting the NTD/N-terminal domain ATP binding site of Hsp90, e.g., geldanamycin and its derivatives such as 17-AAG) [67].